Carcinoid syndrome and costs of care during the first year after diagnosis of neuroendocrine tumors among elderly patients

Chan Shen, Yiyi Chu, Daniel M. Halperin, Arvind Dasari, Shouhao Zhou, Ying Xu, James C. Yao, Ya Chen Tina Shih

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background. Neuroendocrine tumors (NETs) can secrete hormonal peptides that lead to additional symptom burdens. However, it is largely unknown whether and to what extent the additional symptom burdens translate into higher costs of care. This study aimed to examine the cost pattern of elderly NET patients during the first year of diagnosis, taking into account of the carcinoid syndrome status. Methods. We used Surveillance, Epidemiology, and End Results Medicare data to identify elderly NET patients diagnosed between January 2003 and December 2011. Patients who had at least two claims indicative of carcinoid syndrome during the 3 months before and after the NET diagnosis were considered to have carcinoid syndrome. We adopted a payer’s perspective and quantified economic outcomes using the following three measures: (a) total Medicare reimbursement amount, (b) inpatient amount, and (c) outpatient amount. We used a generalized linear model (GLM) to examine the association between syndrome and costs. Results. Our study cohort included 6,749 elderly NET welldifferentiated and moderately differentiated patients. Of these patients, 5,633 (83%) were alive 1 year after diagnosis with continuous enrollment, and 1,116 (17%) died within 1 year. The multivariable GLM showed significant association between the syndrome and higher total, inpatient, and outpatient costs among the group who survived the whole year; the association was insignificant among the group who died within the first year of diagnosis. Conclusion. This population-based study showed that NET patients with carcinoid syndrome incurred higher costs of care especially among those who survived the first year of diagnosis.

Original languageEnglish (US)
Pages (from-to)1451-1462
Number of pages12
JournalOncologist
Volume22
Issue number12
DOIs
StatePublished - Dec 1 2017

Fingerprint

Neuroendocrine Tumors
Carcinoid Tumor
Costs and Cost Analysis
Medicare
Inpatients
Linear Models
Outpatients
Epidemiology
Cohort Studies
Economics
Peptides
Population

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Shen, Chan ; Chu, Yiyi ; Halperin, Daniel M. ; Dasari, Arvind ; Zhou, Shouhao ; Xu, Ying ; Yao, James C. ; Shih, Ya Chen Tina. / Carcinoid syndrome and costs of care during the first year after diagnosis of neuroendocrine tumors among elderly patients. In: Oncologist. 2017 ; Vol. 22, No. 12. pp. 1451-1462.
@article{a1b9df6d656b4ffa8d3a3dcfb900065a,
title = "Carcinoid syndrome and costs of care during the first year after diagnosis of neuroendocrine tumors among elderly patients",
abstract = "Background. Neuroendocrine tumors (NETs) can secrete hormonal peptides that lead to additional symptom burdens. However, it is largely unknown whether and to what extent the additional symptom burdens translate into higher costs of care. This study aimed to examine the cost pattern of elderly NET patients during the first year of diagnosis, taking into account of the carcinoid syndrome status. Methods. We used Surveillance, Epidemiology, and End Results Medicare data to identify elderly NET patients diagnosed between January 2003 and December 2011. Patients who had at least two claims indicative of carcinoid syndrome during the 3 months before and after the NET diagnosis were considered to have carcinoid syndrome. We adopted a payer’s perspective and quantified economic outcomes using the following three measures: (a) total Medicare reimbursement amount, (b) inpatient amount, and (c) outpatient amount. We used a generalized linear model (GLM) to examine the association between syndrome and costs. Results. Our study cohort included 6,749 elderly NET welldifferentiated and moderately differentiated patients. Of these patients, 5,633 (83{\%}) were alive 1 year after diagnosis with continuous enrollment, and 1,116 (17{\%}) died within 1 year. The multivariable GLM showed significant association between the syndrome and higher total, inpatient, and outpatient costs among the group who survived the whole year; the association was insignificant among the group who died within the first year of diagnosis. Conclusion. This population-based study showed that NET patients with carcinoid syndrome incurred higher costs of care especially among those who survived the first year of diagnosis.",
author = "Chan Shen and Yiyi Chu and Halperin, {Daniel M.} and Arvind Dasari and Shouhao Zhou and Ying Xu and Yao, {James C.} and Shih, {Ya Chen Tina}",
year = "2017",
month = "12",
day = "1",
doi = "10.1634/theoncologist.2017-0149",
language = "English (US)",
volume = "22",
pages = "1451--1462",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "12",

}

Carcinoid syndrome and costs of care during the first year after diagnosis of neuroendocrine tumors among elderly patients. / Shen, Chan; Chu, Yiyi; Halperin, Daniel M.; Dasari, Arvind; Zhou, Shouhao; Xu, Ying; Yao, James C.; Shih, Ya Chen Tina.

In: Oncologist, Vol. 22, No. 12, 01.12.2017, p. 1451-1462.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Carcinoid syndrome and costs of care during the first year after diagnosis of neuroendocrine tumors among elderly patients

AU - Shen, Chan

AU - Chu, Yiyi

AU - Halperin, Daniel M.

AU - Dasari, Arvind

AU - Zhou, Shouhao

AU - Xu, Ying

AU - Yao, James C.

AU - Shih, Ya Chen Tina

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Background. Neuroendocrine tumors (NETs) can secrete hormonal peptides that lead to additional symptom burdens. However, it is largely unknown whether and to what extent the additional symptom burdens translate into higher costs of care. This study aimed to examine the cost pattern of elderly NET patients during the first year of diagnosis, taking into account of the carcinoid syndrome status. Methods. We used Surveillance, Epidemiology, and End Results Medicare data to identify elderly NET patients diagnosed between January 2003 and December 2011. Patients who had at least two claims indicative of carcinoid syndrome during the 3 months before and after the NET diagnosis were considered to have carcinoid syndrome. We adopted a payer’s perspective and quantified economic outcomes using the following three measures: (a) total Medicare reimbursement amount, (b) inpatient amount, and (c) outpatient amount. We used a generalized linear model (GLM) to examine the association between syndrome and costs. Results. Our study cohort included 6,749 elderly NET welldifferentiated and moderately differentiated patients. Of these patients, 5,633 (83%) were alive 1 year after diagnosis with continuous enrollment, and 1,116 (17%) died within 1 year. The multivariable GLM showed significant association between the syndrome and higher total, inpatient, and outpatient costs among the group who survived the whole year; the association was insignificant among the group who died within the first year of diagnosis. Conclusion. This population-based study showed that NET patients with carcinoid syndrome incurred higher costs of care especially among those who survived the first year of diagnosis.

AB - Background. Neuroendocrine tumors (NETs) can secrete hormonal peptides that lead to additional symptom burdens. However, it is largely unknown whether and to what extent the additional symptom burdens translate into higher costs of care. This study aimed to examine the cost pattern of elderly NET patients during the first year of diagnosis, taking into account of the carcinoid syndrome status. Methods. We used Surveillance, Epidemiology, and End Results Medicare data to identify elderly NET patients diagnosed between January 2003 and December 2011. Patients who had at least two claims indicative of carcinoid syndrome during the 3 months before and after the NET diagnosis were considered to have carcinoid syndrome. We adopted a payer’s perspective and quantified economic outcomes using the following three measures: (a) total Medicare reimbursement amount, (b) inpatient amount, and (c) outpatient amount. We used a generalized linear model (GLM) to examine the association between syndrome and costs. Results. Our study cohort included 6,749 elderly NET welldifferentiated and moderately differentiated patients. Of these patients, 5,633 (83%) were alive 1 year after diagnosis with continuous enrollment, and 1,116 (17%) died within 1 year. The multivariable GLM showed significant association between the syndrome and higher total, inpatient, and outpatient costs among the group who survived the whole year; the association was insignificant among the group who died within the first year of diagnosis. Conclusion. This population-based study showed that NET patients with carcinoid syndrome incurred higher costs of care especially among those who survived the first year of diagnosis.

UR - http://www.scopus.com/inward/record.url?scp=85038447241&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038447241&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.2017-0149

DO - 10.1634/theoncologist.2017-0149

M3 - Article

C2 - 28642335

AN - SCOPUS:85038447241

VL - 22

SP - 1451

EP - 1462

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 12

ER -